JP2009504664A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504664A5
JP2009504664A5 JP2008526175A JP2008526175A JP2009504664A5 JP 2009504664 A5 JP2009504664 A5 JP 2009504664A5 JP 2008526175 A JP2008526175 A JP 2008526175A JP 2008526175 A JP2008526175 A JP 2008526175A JP 2009504664 A5 JP2009504664 A5 JP 2009504664A5
Authority
JP
Japan
Prior art keywords
phenyl
benzyl
imidazol
amino
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008526175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504664A (ja
JP4975745B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/031129 external-priority patent/WO2007021794A1/en
Publication of JP2009504664A publication Critical patent/JP2009504664A/ja
Publication of JP2009504664A5 publication Critical patent/JP2009504664A5/ja
Application granted granted Critical
Publication of JP4975745B2 publication Critical patent/JP4975745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008526175A 2005-08-09 2006-08-09 Kspインヒビターとしての置換イミダゾール化合物 Expired - Fee Related JP4975745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70690105P 2005-08-09 2005-08-09
US60/706,901 2005-08-09
PCT/US2006/031129 WO2007021794A1 (en) 2005-08-09 2006-08-09 Substituted imidazole compounds as ksp inhibitors

Publications (3)

Publication Number Publication Date
JP2009504664A JP2009504664A (ja) 2009-02-05
JP2009504664A5 true JP2009504664A5 (enExample) 2012-02-23
JP4975745B2 JP4975745B2 (ja) 2012-07-11

Family

ID=37421032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008526175A Expired - Fee Related JP4975745B2 (ja) 2005-08-09 2006-08-09 Kspインヒビターとしての置換イミダゾール化合物

Country Status (19)

Country Link
US (1) US7626040B2 (enExample)
EP (1) EP1912972B1 (enExample)
JP (1) JP4975745B2 (enExample)
KR (1) KR20080036611A (enExample)
CN (1) CN101253167A (enExample)
AR (1) AR056025A1 (enExample)
AT (1) ATE526324T1 (enExample)
AU (1) AU2006279991B2 (enExample)
BR (1) BRPI0614547A2 (enExample)
CA (1) CA2618747A1 (enExample)
ES (1) ES2374449T3 (enExample)
GT (1) GT200600366A (enExample)
MY (1) MY147188A (enExample)
PE (1) PE20070352A1 (enExample)
PL (1) PL1912972T3 (enExample)
PT (1) PT1912972E (enExample)
RU (1) RU2413721C9 (enExample)
TW (1) TW200800951A (enExample)
WO (1) WO2007021794A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
GEP20125415B (en) * 2007-01-05 2012-03-12 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
US8252832B2 (en) * 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
EP2558450A1 (en) 2010-04-15 2013-02-20 Novartis AG Triazole compounds as ksp inhibitors
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
AU2014372833B2 (en) * 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
SG11201710639YA (en) * 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CA2990398A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN109481436A (zh) * 2018-08-21 2019-03-19 广东医科大学 血栓素a2合成酶抑制剂奥扎格雷在制备治疗吸烟所致肺癌药物中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP0946587A2 (en) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
HUP0202648A3 (en) * 1998-06-12 2003-02-28 Sod Conseils Rech Applic Imidazolyl derivatives, pharmaceutical compositions containing them and their use
EP1226129B1 (en) * 1999-10-27 2006-05-24 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2001227812A1 (en) 2000-05-02 2001-11-12 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
US7566734B2 (en) * 2000-08-01 2009-07-28 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
RU2005100783A (ru) * 2002-06-14 2005-07-20 Мерк энд Ко., Инк. (US) Ингибиторы митотического кинезина
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
EP1620092A4 (en) * 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004103282A2 (en) * 2003-05-15 2004-12-02 Cytokinetics, Inc. Compounds, compositions and methods
EP1740550A1 (en) 2004-04-14 2007-01-10 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.

Similar Documents

Publication Publication Date Title
RU2375352C2 (ru) Амидные производные
JP2023501253A5 (enExample)
JP2025016684A5 (enExample)
RU2427572C2 (ru) N-(1-(1-бензил-4-фенил-1н-имидазол-2-ил)-2,2-диметилпропил)бензамидные производные и родственные соединения в качестве ингибиторов кинезинового белка веретена (ksp) для лечения рака
RU2008108939A (ru) Замещенные имидазолы, фармацевтическая композиция, способ лечения заболевания, связанного по крайней мере с активностью ksp, способ ингибирования ksp, лекарственное средство для лечения рака
KR101985050B1 (ko) 피라진카르복사미드 화합물
JP2022531801A5 (enExample)
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
RU2433128C2 (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
KR102510858B1 (ko) 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
JP2019517596A5 (enExample)
JP2016536333A5 (enExample)
RU2003127116A (ru) Гетероциклические ингибиторы erk2 и их использование
JP2008528467A5 (enExample)
HRP20140737T1 (hr) Inhibitori hepatitis c virusa
JP2011526616A (ja) 化学化合物
RU2005130486A (ru) Хиназолины, полезные в качестве модуляторов ионных каналов
JP2012528166A5 (enExample)
US20210261542A1 (en) Compounds which inhibit rna polymerase, compositions including such compounds, and their use
JP2009513575A5 (enExample)
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
CA2989469A1 (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
JP2018520201A5 (enExample)
HRP20250104T1 (hr) Novi supstituirani derivati sulfonilureje
RU2007104838A (ru) 2,4,6-тризамещенные пиримидины в качестве ингибиторовфосфотидилинозитол (pi) 3-киназы и их применение для лечения злокачественного новообразования